This invention relates generally to implantable medication delivery systems, sometimes referred to as infusion pumps, and more particularly to a method and apparatus for enhancing safe operation by preventing unintended medication delivery attributable to reservoir overpressurization.
Implantable medication delivery devices are widely discussed in the technical and patent literature. They typically include a housing containing a medication reservoir which can be filled transcutaneously by a hypodermic needle penetrating a fill port septum. The medication reservoir is generally coupled via an internal flow path to a device outlet port for delivering medication to the patient. A typical delivery device further includes some type of mechanism, e.g., a propellant chamber, for moving the medication from the reservoir through the internal flow path to the device outlet port for delivery to the patient.
The literature recognizes that overfilling the medication reservoir can result in unintended medication delivery from the device outlet port to the patient. Accordingly, various techniques have been proposed for avoiding problems associated with overfilling. For example, U.S. Pat. No. 5,158,547 describes an overfill protection mechanism comprising a valve associated with the fill port which automatically responds to a “reservoir full” condition to dose the fill port to prevent overfilling.
The present invention is directed to an implantable medication delivery apparatus including a flow path coupling a medication reservoir to a device outlet port where the flow path includes a regulator means for limiting the magnitude of pressure transferred downstream from the medication reservoir. Limiting the magnitude of pressure transfer prevents overpressurization of the reservoir from inducing an unintended delivery of medication from the device outlet port. More particularly, the regulator means is configured to respond to the reservoir pressure exceeding a certain threshold for closing a valve located downstream from the reservoir. The valve closure functions to isolate the device outlet port from further reservoir pressure increases which otherwise could induce unintended medication flow from the device outlet port.
In a preferred embodiment of the invention, the regulator means includes (1) a regulator medication chamber in the flow path between the reservoir outlet and the device outlet port: and (2) a regulator valve in the flow path between the reservoir outlet and the regulator chamber. In normal operation, the regulator valve is open and the pressure in the regulator chamber is substantially identical to the reservoir pressure. In the event of reservoir overpressurization attributable, for example, to abusive overfilling, the reservoir pressure and regulator chamber pressure will increase. When the regulator chamber pressure exceeds a certain threshold, the regulator valve closes to prevent further medication flow from the reservoir to the regulator chamber. Thus, any further rise in reservoir pressure will not increase regulator chamber pressure. After closure of the regulator valve, pressure within the regulator chamber will diminish as medication is periodically withdrawn therefrom for delivery to the device outlet port in accordance with the normal functioning (e.g., preprogrammed) of a medication delivery controller.
A regulator valve in accordance with the invention can be implemented in a variety of ways; e.g., it can include a pressure responsive element such as a bellows or a diaphragm mounted to move (e.g., expand or contract) in response to a sufficient pressure differential. The pressure responsive element is coupled to a valve element for movement between a seated (valve closed) state and an unseated (valve open) state. For example, the valve element can comprise a compliant disk mounted on an expansible bellows. During normal operation, when the reservoir and regulator chamber pressures are equal and less than a certain threshold pressure, the bellows unseats the disk, thus opening the medication flow path. However, when the regulator chamber pressure exceeds the certain threshold, the bellows contracts to seat the disk to thus close the flow path and prevent the elevated reservoir pressure from provoking unintended medication delivery through the flow path to the patient.
In accordance with the invention, the threshold level is based on a reference pressure which can be established in various ways. In one preferred embodiment, the reference pressure is derived from a substantially constant pressure available in a closed fixed volume chamber established at the time of manufacture. In a preferred embodiment, the closed chamber can comprise the compartment accommodating the electronics in the delivery device housing. Alternatively, the reference pressure can be derived from the outlet catheter, or from a site interior to the patient's body, e.g., the site of infusion, or exterior to the patient's body.
Various alternative regulator implementations can be employed in accordance with the invention to provide a pressure responsive element to move a valve element. The pressure responsive element can utilize, for example, a bellows or a diaphragm, which can either be attached to the valve element or bear against a biased valve element. Alternatively, the regulator can be implemented with a pressure responsive switch for controlling a solenoid to control position of a valve element.
Preferred embodiments of the invention utilize a pump located in the medication flow path between the regulator valve and the device outlet port. The pump is preferably powered by a battery carried by the implantable delivery device. A preferred regulator means in accordance with the invention derives its operating energy from the overpressurized reservoir and does not utilize battery power.
Attention is initially directed to
The device 10, as depicted in
As shown in
In normal operation of the system of
In the normal operation of the medication delivery controller 50 and pump 46, increments of medication will be pumped from the chamber 42 and through the outlet port 16. Accordingly, over time, the pressure in chamber 42 will diminish. When the chamber pressure diminishes sufficiently, the flow controller 60 will open valve 36 to thereby again enable medication flow from the reservoir 24 to the chamber 42, thus initiating the process of relieving the overpressurization in the reservoir.
Whereas
The valve mechanism 78 is depicted as including a stem 104 which is suspended below the offset portion 102 of the wall 100. The lower end of the stem 104 defines a flange 105 which supports a valve element, e.g., a compliant disk 106. When the valve mechanism 78 is in its normally open position as illustrated in
With reference to
On the other hand, when a reservoir overpressurization condition occurs, i.e., the reservoir pressure exceeds a certain threshold, the pressure differential created across the plate portion 102 will be sufficient to pull valve element 106 upwardly to its seated position. More particularly, the upper surface of plate portion 102 sees the reference pressure available in the electronics compartment 74. The pressure condition in reservoir 24 acts on the lower surface of plate portion 102. The operational characteristics of the valve mechanism 78 are preferably selected so that the threshold pressure is slightly less than the reference pressure, i.e., valve closure preferably occurs prior to the reservoir pressure exceeding the reference pressure. When the valve element 106 is pulled upwardly against valve nib 108 (
The pump 46 located downstream from the regions 114 and 116 draws medication therefrom under the control of the aforementioned medication delivery controller 50. Thus, the patient is able to receive the intended medication delivery despite the overpressurization of reservoir 24. As medication is withdrawn from the regions 114 and 116 and delivered to the patient, the pressure differential across plate 100 will diminish. When it diminishes sufficiently, the reference pressure on the upper surface of plate 100 will be sufficient to drive the stem 104 downwardly to unseat the valve element 106 as shown in
Whereas the embodiment thus far described with reference to
Attention is now directed to
It should be noted that the diaphragm lower surface 166 is exposed to reservoir pressure via path portion 159 and the diaphragm upper surface 168 is exposed to a reference pressure; e.g., the pressure in the device electronics chamber as previously discussed.
In normal operation when the reservoir pressure is less than the reference pressure, the diaphragm 152 is flexed downwardly to bear against valve element 160 to compress spring 162 to unseat the element 160 and open the flow path from the reservoir to the cavity 154. However, when the reservoir pressure increases above a certain threshold, the diaphragm 152 flexes upwardly, to enable the spring 162 to seat the valve element 160 against valve seat 164. This action isolates the flow path portions downstream from valve element 160 from further reservoir pressure increases.
Attention is now directed to
The diaphragm 182 has a stem 190 depending therefrom which terminates in a ball valve element 192. The diaphragm 182 is normally flexed downwardly as illustrated to unseat the ball element 192 from valve seat 188. However, as with the previously discussed embodiments, when the reservoir pressure applied to the underside of diaphragm 182 (via path portion 186 and medication chamber 185) exceeds the reference pressure applied to the upper surface of diaphragm 182, the diaphragm flexes upwardly to pull the ball element 192 and seat it against valve seat 188. This action then isolates the medication chamber 185 from further pressure increases in the reservoir.
From the foregoing, it should now be appreciated that an implantable medication delivery device apparatus and method have been described herein incorporating a flow path between a reservoir and an outlet port which includes a regulator means operable to contain excessive reservoir pressure excursions. The regulator means functions to prevent excessive reservoir pressure from acting downstream to force medication through the outlet port. Although only a limited number of embodiments have been specifically described herein, it should be recognized that the invention can be implemented in a variety of alternative manners which fall within the intended scope of the appended claims. For example only, in addition to using a bellows and/or diaphragm for pressure sensing and valve element control, the regulator means can be implemented using a pressure responsive switch to control a solenoid and valve element.
This application is a continuation of PCT/US2004/009534 filed 24 Mar. 2004 and claims priority based on U.S. Application 60/458,151 filed 27 Mar. 2003.
Number | Name | Date | Kind |
---|---|---|---|
3650699 | Beer | Mar 1972 | A |
3731681 | Blackshear et al. | May 1973 | A |
4074694 | Lee | Feb 1978 | A |
4077405 | Haerten et al. | Mar 1978 | A |
4152098 | Moody et al. | May 1979 | A |
4193397 | Tucker et al. | Mar 1980 | A |
4221219 | Tucker | Sep 1980 | A |
4265241 | Portner et al. | May 1981 | A |
4299220 | Dorman | Nov 1981 | A |
4350155 | Thompson | Sep 1982 | A |
4373527 | Fischell | Feb 1983 | A |
4525165 | Fischell | Jun 1985 | A |
4606371 | Maekawa | Aug 1986 | A |
4714462 | DiDomenico | Dec 1987 | A |
4718893 | Dorman et al. | Jan 1988 | A |
4772263 | Dorman et al. | Sep 1988 | A |
4832054 | Bark | May 1989 | A |
4846806 | Wigness et al. | Jul 1989 | A |
4968301 | di Palma et al. | Nov 1990 | A |
4978338 | Melsky et al. | Dec 1990 | A |
5061242 | Sampson | Oct 1991 | A |
5067943 | Burke | Nov 1991 | A |
5088983 | Burke | Feb 1992 | A |
5158547 | Doan et al. | Oct 1992 | A |
5342298 | Michaels et al. | Aug 1994 | A |
5586629 | Shoberg et al. | Dec 1996 | A |
5725017 | Elsberry et al. | Mar 1998 | A |
5785681 | Indravudh | Jul 1998 | A |
5820589 | Torgerson et al. | Oct 1998 | A |
5957890 | Mann et al. | Sep 1999 | A |
6048328 | Haller et al. | Apr 2000 | A |
6152885 | Taepke | Nov 2000 | A |
6152898 | Olsen | Nov 2000 | A |
6203523 | Haller et al. | Mar 2001 | B1 |
6228050 | Olsen et al. | May 2001 | B1 |
6254576 | Shekalim | Jul 2001 | B1 |
6290652 | Wellnhofer | Sep 2001 | B1 |
6398738 | Millar | Jun 2002 | B1 |
6488652 | Weijand et al. | Dec 2002 | B1 |
6572583 | Olsen et al. | Jun 2003 | B1 |
20020088497 | Grey et al. | Jul 2002 | A1 |
20030050623 | Lord et al. | Mar 2003 | A1 |
Number | Date | Country |
---|---|---|
WO 9938552 | Aug 1999 | WO |
WO 0074751 | Dec 2000 | WO |
Number | Date | Country | |
---|---|---|---|
20050273083 A1 | Dec 2005 | US |
Number | Date | Country | |
---|---|---|---|
60458151 | Mar 2003 | US |
Number | Date | Country | |
---|---|---|---|
Parent | PCT/US2004/009534 | Mar 2004 | US |
Child | 11203532 | US |